p.83 抽出テキスト
CLINICAL STATEMENTS AND GUIDELINES September 16, 2025 Circulation. 2025;152:e114–e218. DOI: 10.1161/CIR.0000000000001356 e196 96 Ndanuko RN, Ibrahim R, Hapsari RA, et al. Association between the urinary sodium to potassium ratio and blood pressure in adults: a systematic re view and meta-analysis. Adv Nutr. 2021;12:1751–1767. 97. Stamler J, Chan Q, Daviglus ML, et al. Relation of dietary sodium (salt) to blood pressure and its possible modulation by other dietary factors. Hypertension. 2018;71:631–637. 98. Gan L, Zhao B, Inoue-Choi M, et al. Sex-specific associations between so dium and potassium intake and overall and cause-specific mortality: a large prospective US cohort study, systematic review, and updated meta-analysis of cohort studies. BMC Med. 2024;22:132. 99. Zhang Z, Cogswell ME, Gillespie C, et al. Association between usual so dium and potassium intake and blood pressure and hypertension among US adults: NHANES 2005-2010. PLoS One. 2013;8:e75289. 100. Vinceti M, Filippini T, Crippa A, et al. Meta-analysis of potassium intake and the risk of stroke. J Am Heart Assoc. 2016;5:e004210. 101. Cecchini M, Filippini T, Whelton PK, et al. Alcohol intake and risk of hyper tension: a systematic review and dose-response meta-analysis of nonex perimental cohort studies. Hypertension. 2024;81:1701–1715. 102. Acin MT, Rueda JR, Saiz LC, et al. Alcohol intake reduction for controlling hypertension. Cochrane Database Syst Rev. 2020;9:CD010022. 103. Cushman WC, Cutler JA, Hanna E, et al. Prevention and Treatment of Hypertension Study (PATHS): effects of an alcohol treatment program on blood pressure. Arch Intern Med. 1998;158:1197–1207. 104. Anderson BO, Berdzuli N, Ilbawi A, et al. Health and cancer risks associated with low levels of alcohol consumption. Lancet Public Health. 2023;8:e6-e7. 105. Saco-Ledo G, Valenzuela PL, Ruiz-Hurtado G, et al. Exercise reduces ambulatory blood pressure in patients with hypertension: a systematic re view and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2020;9:e018487. 106. Henkin JS, Pinto RS, Machado CLF, et al. Chronic effect of resistance training on blood pressure in older adults with prehypertension and hypertension: a systematic review and meta-analysis. Exp Gerontol. 2023;177:112193. 107. MacDonald HV, Johnson BT, Huedo-Medina TB, et al. Dynamic resistance training as stand-alone antihypertensive lifestyle therapy: a meta-analysis. J Am Heart Assoc. 2016;5:e003231. 108. Inder JD, Carlson DJ, Dieberg G, et al. Isometric exercise training for blood pressure management: a systematic review and meta-analysis to optimize benefit. Hypertens Res. 2016;39:88–94. 109. Edwards J, De Caux A, Donaldson J, et al. Isometric exercise versus highintensity interval training for the management of blood pressure: a system atic review and meta-analysis. Br J Sports Med. 2022;56:506–514. 110. Hansford HJ, Parmenter BJ, McLeod KA, et al. The effectiveness and safe ty of isometric resistance training for adults with high blood pressure: a sys tematic review and meta-analysis. Hypertens Res. 2021;44:1373–1384. 111. Larsen RN, Kingwell BA, Sethi P, et al. Breaking up prolonged sitting reduces resting blood pressure in overweight/obese adults. Nutr Metab Cardiovasc Dis. 2014;24:976–982. 112. Zeigler ZS, Mullane SL, Crespo NC, et al. Effects of standing and lightintensity activity on ambulatory blood pressure. Med Sci Sports Exerc. 2016;48:175–181. 113. Dempsey PC, Sacre JW, Larsen RN, et al. Interrupting prolonged sitting with brief bouts of light walking or simple resistance activities reduces resting blood pressure and plasma noradrenaline in type 2 diabetes. J Hypertens. 2016;34:2376–2382. 114. Bhammar DM, Sawyer BJ, Tucker WJ, et al. Breaks in sitting time: effects on continuously monitored glucose and blood pressure. Med Sci Sports Exerc. 2017;49:2119–2130. 115. Wheeler MJ, Dunstan DW, Ellis KA, et al. Effect of morning exercise with or without breaks in prolonged sitting on blood pressure in older overweight/ obese adults. Hypertension. 2019;73:859–867. 116. Egan B. Are there cardiometabolic benefits of low-intensity physical activ ity in at-risk adults? J Am Soc Hypertens. 2018;12:69–70. 117. Cornelissen VA, Arnout J, Holvoet P, et al. Influence of exercise at lower and higher intensity on blood pressure and cardiovascular risk factors at older age. J Hypertens. 2009;27:753–762. 118. Costa EC, Hay JL, Kehler DS, et al. Effects of high-intensity inter val training versus moderate-intensity continuous training on blood pressure in adults with pre- to established hypertension: a sys tematic review and meta-analysis of randomized trials. Sports Med. 2018;48:2127–2142. 119. Brook RD, Appel LJ, Rubenfire M, et al. Beyond medications and diet: alternative approaches to lowering blood pressure. Hypertension. 2013;61:1360–1383. 120. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on life style management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S76–S99. 121. Filippini T, Malavolti M, Whelton PK, et al. Sodium intake and risk of hyper tension: a systematic review and dose-response meta-analysis of observa tional cohort studies. Curr Hypertens Rep. 2022;24:133–144. 122. Rijal A, Adhikari TB, Dhakal S, et al. Effects of adding exercise to usual care on blood pressure in patients with hypertension, type 2 diabetes, or cardio vascular disease: a systematic review with meta-analysis and trial sequential analysis. J Hypertens. 2024;42:10–22. 123. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269– 1324. 5.2.1 Initiation of Pharmacologic BP Treatment in the Context of Overall CVD Risk 1. Blood Pressure Lowering Treatment Trialists Collaboration. Blood pressure- lowering treatment based on cardiovascular risk: a meta-analysis of indi vidual patient data. Lancet. 2014;384:591–598. 2. Eddy DM, Adler J, Patterson B, et al. Individualized guidelines: the potential for increasing quality and reducing costs. Ann Intern Med. 2011;154:627– 634. 3. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–967. 4. Karmali KN, Lloyd-Jones DM, van der Leeuw J, et al. Blood pressurelowering treatment strategies based on cardiovascular risk versus blood pressure: a meta-analysis of individual participant data. PLoS Med. 2018;15:e1002538. 5. Karmali KN, Ning H, Goff DC, et al. Identifying individuals at risk for cardio vascular events across the spectrum of blood pressure levels. J Am Heart Assoc. 2015;4:e002126. 6. van Dieren S, Kengne AP, Chalmers J, et al. Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes. Diabetes Res Clin Pract. 2012;98:83–90. 7. Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103– 2116. 8. Peng X, Jin C, Song Q, et al. Stage 1 hypertension and the 10-year and lifetime risk of cardiovascular disease: a prospective real-world study. J Am Heart Assoc. 2023;12:e028762. 9. Bress AP, Bellows BK, King JB, et al. Cost-effectiveness of intensive versus standard blood-pressure control. N Engl J Med. 2017;377:745–755. 5.2.2 BP Treatment Threshold and the Use of CVD Risk Estimation to Guide Treatment of Hypertension 1. He J, Ouyang N, Guo X, et al. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial. Lancet. 2023;401:928–938. 2. Lonn EM, Bosch J, Lopez-Jaramillo P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009–2020. 3. Rahimi K, Bidel Z, Nazarzadeh M, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397:1625–1636. 4. Guo X, Ouyang N, Sun G, et al. Multifaceted intensive blood pressure con trol model in older and younger individuals with hypertension: a randomized clinical trial. JAMA Cardiol. 2024;9:781–790. 5. Liu J, Li Y, Ge J, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blindedoutcome, randomised trial. Lancet. 2024;404:245–255. 6. Peng X, Jin C, Song Q, et al. Stage 1 hypertension and the 10-year and lifetime risk of cardiovascular disease: a prospective real-world study. J Am Heart Assoc. 2023;12:e028762. 7. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–2116. Downloaded from http://ahajournals.org by on October 7, 2026